AN2 Therapeutics(ANTX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights Cash, cash equivalents, and investments of $104.5 million at June 30, 2024; cash runway anticipated to fund operations through 2027 Menlo Park, CA – August 13, 2024 – AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform today reported financial results for the q ...